Hepatocellular Carcinoma–Circulating Tumor Cells Expressing PD‐L1 Are Prognostic and Potentially Associated With Response to Checkpoint Inhibitors
Hepatocellular carcinoma (HCC) is a leading cause of mortality. Checkpoint inhibitors of programmed cell death protein‐1 (PD‐1) and programmed death‐ligand 1 (PD‐L1) have shown great efficacy, but lack biomarkers that predict response. Circulating tumor cells (CTCs) have promise as a liquid‐biopsy b...
Main Authors: | Paul Winograd, Shuang Hou, Colin M. Court, Yi‐Te Lee, Pin‐Jung Chen, Yazhen Zhu, Saeed Sadeghi, Richard S. Finn, Pai‐Chi Teng, Jasmin J. Wang, Zhicheng Zhang, Hongtao Liu, Ronald W. Busuttil, James S Tomlinson, Hsian‐Rong Tseng, Vatche G. Agopian |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2020-10-01
|
Series: | Hepatology Communications |
Online Access: | https://doi.org/10.1002/hep4.1577 |
Similar Items
-
The Role of Extracellular Vesicles in Disease Progression and Detection of Hepatocellular Carcinoma
by: Yi-Te Lee, et al.
Published: (2021-06-01) -
Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges
by: Zuzana Macek Jilkova, et al.
Published: (2019-10-01) -
Exploratory Analysis of Lenvatinib Therapy in Patients with Unresectable Hepatocellular Carcinoma Who Have Failed Prior PD−1/PD-L1 Checkpoint Blockade
by: Tomoko Aoki, et al.
Published: (2020-10-01) -
PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
by: Jinhua Liu, et al.
Published: (2021-09-01) -
Acquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade?
by: Jake S. O’Donnell, et al.
Published: (2016-10-01)